Guru P. Sonpavde, MD serves as the Medical Director of Genitourinary (GU) Oncology, Assistant Director of the Clinical Research Unit and Christopher K. Glanz Chair for Bladder Cancer Research at the AdventHealth Cancer Institute. Previously, he was Bladder Cancer Director at the Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School from 2017-2022, GU Oncology Director and Associate Professor of Medicine at the University of Alabama at Birmingham from 2012 to 2017 and practiced from 2004 to 2012 at Texas Oncology. His focus is drug development and translational research to cure GU cancers, which have led to approximately 500 publications. He is a member of Southwest Oncology Group, Scientific Advisory Board of the Bladder Cancer Advocacy Network (BCAN), and the Bladder Cancer Task Force of U.S. NCI GU Steering Committee. He was cited in TIME magazine regarding his participation in clinical trials in August 2022.
